CD274 and neoplasm: According to preclinical data, paclitaxel supports the upregulation of co-inhibitory ligands like PD-L1 by tumor-infiltrating myeloid cells or malignant cells as a consequence of type I IFN or IFN-γ signaling (126, 127).